Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain inflammation and was associated with ...

Ublituximab shows five year relapse reduction and disability benefits in multiple sclerosis, supporting early high efficacy treatment strategies today.

UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...

Research suggests that walking backward therapy can help people with multiple sclerosis improve their balance.

Researchers evaluated whether hormonal biomarkers in women with relapsing-remitting MS varied significantly when accounting for menstrual phase or menopausal status.

The difficulty is that EBV lives latently in B cells in the blood at a frequency, in most immunocompetent individuals, of about 1 in 100,000 to 1 in a million. That level of infection is below the ...

Jack Osbourne, son of Ozzy, was first diagnosed with RRMS at the age of 26. However, he hasn't let it stop him. We explain the disease and how it's treated.

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing ...

Results from a new small study suggest people aged 50 and older with MS who want to discontinue disease-modifying therapy can do so with cladribine with minimal risk for relapse.

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...

Professional societies of neurologists, including most prominently the American Academy of Neurology (AAN) and the European Academy of Neurology (EAN) periodically release recommendations to guide ...